Discovery of novel synthetic IL-1 adjuvants

承包商将确定可用于增强人类疫苗效力的新佐剂候选药物。在该奖项下进行的研究将有助于开发新的佐剂线索，这些线索要么：(A)利用天然免疫系统的天然能力，启动和维持有效的T和B细胞反应，并诱导长期免疫记忆；要么(B)直接作用于适应性免疫系统的细胞，以增强它们对病原体衍生抗原的反应。 研究包括在相关动物模型中测试试验性或FDA批准的预防性或治疗性疫苗的候选佐剂，以确定疫苗对一种或多种与人类疾病相关的病原体的潜在效力。

The contractor will identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research performed under this award will contribute to the pipeline of new adjuvant leads that either: (a) exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) act directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens. Studies include testing of adjuvant candidates with experimental or FDA approved preventative or therapeutic vaccines in relevant animal models to determine the potential efficacy of the vaccine against one or more pathogens relevant to human disease.